Matching articles for "Dovonex"

Drugs for Plaque Psoriasis

   
The Medical Letter on Drugs and Therapeutics • September 30, 2024;  (Issue 1712)
Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis...
Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with topical therapy, phototherapy, and systemic drugs have recently been published.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):153-60 | Show Full IntroductionHide Full Introduction

Topical Roflumilast (Zoryve) for Plaque Psoriasis

   
The Medical Letter on Drugs and Therapeutics • January 23, 2023;  (Issue 1668)
The FDA has approved a 0.3% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of plaque psoriasis in patients ≥12 years old. Roflumilast...
The FDA has approved a 0.3% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of plaque psoriasis in patients ≥12 years old. Roflumilast is the first topical PDE4 inhibitor to be approved by the FDA for this indication; crisaborole (Eucrisa), another topical PDE4 inhibitor, is approved for treatment of atopic dermatitis. Oral roflumilast (Daliresp) is approved for treatment of chronic obstructive pulmonary disease.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):10-2 | Show Full IntroductionHide Full Introduction

Tapinarof Cream (Vtama) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • August 8, 2022;  (Issue 1656)
The FDA has approved Vtama (Dermavant), a 1% cream formulation of the aryl hydrocarbon receptor (AhR) agonist tapinarof, for treatment of adults with plaque psoriasis. It is the first AhR agonist to...
The FDA has approved Vtama (Dermavant), a 1% cream formulation of the aryl hydrocarbon receptor (AhR) agonist tapinarof, for treatment of adults with plaque psoriasis. It is the first AhR agonist to be approved by the FDA.
Med Lett Drugs Ther. 2022 Aug 8;64(1656):122-4 | Show Full IntroductionHide Full Introduction

Drugs for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • June 17, 2019;  (Issue 1574)
Mild to moderate psoriasis can be treated with topical drugs or with phototherapy. Patients with moderate to severe disease generally require systemic...
Mild to moderate psoriasis can be treated with topical drugs or with phototherapy. Patients with moderate to severe disease generally require systemic therapy.
Med Lett Drugs Ther. 2019 Jun 17;61(1574):89-96 | Show Full IntroductionHide Full Introduction

Expanded Table: Some Drugs for Psoriasis (online only)

   
The Medical Letter on Drugs and Therapeutics • June 17, 2019;  (Issue 1574)
...
View the Expanded Table: Some Drugs for Psoriasis
Med Lett Drugs Ther. 2019 Jun 17;61(1574):e96-103 | Show Full IntroductionHide Full Introduction

Risankizumab (Skyrizi) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • June 3, 2019;  (Issue 1573)
The FDA has approved the interleukin (IL)-23 antagonist risankizumab-rzaa (Skyrizi – Abbvie) for treatment of moderate to severe plaque psoriasis in adults. Risankizumab is the third IL-23 antagonist...
The FDA has approved the interleukin (IL)-23 antagonist risankizumab-rzaa (Skyrizi – Abbvie) for treatment of moderate to severe plaque psoriasis in adults. Risankizumab is the third IL-23 antagonist to be approved for this indication; guselkumab (Tremfya) and tildrakizumab (Ilumya) were approved earlier.
Med Lett Drugs Ther. 2019 Jun 3;61(1573):81-3 | Show Full IntroductionHide Full Introduction

Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • January 14, 2019;  (Issue 1563)
Tildrakizumab-asmn (Ilumya – Sun), an interleukin (IL)-23 antagonist, has been approved by the FDA for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy...
Tildrakizumab-asmn (Ilumya – Sun), an interleukin (IL)-23 antagonist, has been approved by the FDA for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tildrakizumab is the second selective IL-23 antagonist to be approved for this indication; guselkumab (Tremfya) was the first.
Med Lett Drugs Ther. 2019 Jan 14;61(1563):4-6 | Show Full IntroductionHide Full Introduction

Calcipotriene/Betamethasone Foam (Enstilar) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • April 11, 2016;  (Issue 1492)
The FDA has approved Enstilar (Leo), an aerosol foam formulation of the synthetic vitamin D3 analog calcipotriene and the high-potency corticosteroid betamethasone dipropionate, for topical treatment of...
The FDA has approved Enstilar (Leo), an aerosol foam formulation of the synthetic vitamin D3 analog calcipotriene and the high-potency corticosteroid betamethasone dipropionate, for topical treatment of plaque psoriasis in adults. Topical ointment and suspension formulations of the same combination have been available for many years.
Med Lett Drugs Ther. 2016 Apr 11;58(1492):48-9 | Show Full IntroductionHide Full Introduction

Drugs for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • June 8, 2015;  (Issue 1470)
Mild to moderate psoriasis is generally treated with topical corticosteroids. Vitamin D analogs and tazarotene are topical alternatives that can be used in combination with topical corticosteroids....
Mild to moderate psoriasis is generally treated with topical corticosteroids. Vitamin D analogs and tazarotene are topical alternatives that can be used in combination with topical corticosteroids. Phototherapy and systemic therapy, including biologic agents, are recommended for patients with moderate to severe disease.
Med Lett Drugs Ther. 2015 Jun 8;57(1470):81-4 | Show Full IntroductionHide Full Introduction

Addendum: Cost of Ustekinumab (Stelara)

   
The Medical Letter on Drugs and Therapeutics • March 8, 2010;  (Issue 1333)
In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7), footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg...
In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7), footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.
Med Lett Drugs Ther. 2010 Mar 8;52(1333):20 | Show Full IntroductionHide Full Introduction

Ustekinumab (Stelara) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • January 25, 2010;  (Issue 1330)
The FDA has approved the use of ustekinumab (Stelara - Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe plaque psoriasis....
The FDA has approved the use of ustekinumab (Stelara - Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe plaque psoriasis. It is the first agent in its class for this indication; the other biologic agents for psoriasis are Tcell or tumor necrosis factor (TNF) inhibitors.
Med Lett Drugs Ther. 2010 Jan 25;52(1330):7-8 | Show Full IntroductionHide Full Introduction

Calcitriol (Vectical) for Mild to Moderate Plaque Psoriasis

   
The Medical Letter on Drugs and Therapeutics • September 7, 2009;  (Issue 1320)
The FDA has approved calcitriol ointment (Vectical - Galderma), a vitamin D analog, for topical treatment of mild-to-moderate plaque psoriasis in adults ≥18 years old. Ointments are generally considered more...
The FDA has approved calcitriol ointment (Vectical - Galderma), a vitamin D analog, for topical treatment of mild-to-moderate plaque psoriasis in adults ≥18 years old. Ointments are generally considered more potent than creams or solutions.
Med Lett Drugs Ther. 2009 Sep 7;51(1320):70-1 | Show Full IntroductionHide Full Introduction

Drugs for Acne, Rosacea and Psoriasis

   
The Medical Letter on Drugs and Therapeutics • November 1, 2008;  (Issue 75)
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium...
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium acnes promote development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Treat Guidel Med Lett. 2008 Nov;6(75):75-82 | Show Full IntroductionHide Full Introduction

A Betamethasone-Calcipotriene Combination for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • July 3, 2006;  (Issue 1238)
Taclonex ointment (Warner Chilcott/LEO Pharma), a combination of the vitamin D3 analog calcipotriene 0.005% (Dovonex) and the high-potency corticosteroid betamethasone dipropionate 0.064%, was recently approved...
Taclonex ointment (Warner Chilcott/LEO Pharma), a combination of the vitamin D3 analog calcipotriene 0.005% (Dovonex) and the high-potency corticosteroid betamethasone dipropionate 0.064%, was recently approved by the FDA for treatment of psoriasis vulgaris in patients ≥ 18 years old.
Med Lett Drugs Ther. 2006 Jul 3;48(1238):55-6 | Show Full IntroductionHide Full Introduction

Drugs for Acne, Rosacea and Psoriasis

   
The Medical Letter on Drugs and Therapeutics • July 1, 2005;  (Issue 35)
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, Propionibacterium acnes bacteria, sebum production, androgens and inflammation have all been implicated. P. acnes, a gram-positive...
The pathogenesis of acne is multifactorial: follicular hyperkeratinization, Propionibacterium acnes bacteria, sebum production, androgens and inflammation have all been implicated. P. acnes, a gram-positive microaerophilic bacterium, plays an important role in the development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
Treat Guidel Med Lett. 2005 Jul;3(35):49-56 | Show Full IntroductionHide Full Introduction

Alefacept (Amevive) For Treatment of Psoriasis

   
The Medical Letter on Drugs and Therapeutics • April 14, 2003;  (Issue 1154)
Alefacept (a le' fa sept; Amevive - Biogen) has been approved by the FDA for parenteral treatment of adults with moderate to severe chronic plaque...
Alefacept (a le' fa sept; Amevive - Biogen) has been approved by the FDA for parenteral treatment of adults with moderate to severe chronic plaque psoriasis.
Med Lett Drugs Ther. 2003 Apr 14;45(1154):31-2 | Show Full IntroductionHide Full Introduction

Two New Retinoids for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • November 7, 1997;  (Issue 1013)
The US Food and Drug Administration (FDA) has approved two new retinoids for treatment of psoriasis. Tazarotene gel 0.05% and 0.1% (Tazorac - Allergan) is being marketed for topical use in patients with...
The US Food and Drug Administration (FDA) has approved two new retinoids for treatment of psoriasis. Tazarotene gel 0.05% and 0.1% (Tazorac - Allergan) is being marketed for topical use in patients with stable, mild to moderate plaque psoriasis. Acitretin (Soriatane - Roche) is being promoted for systemic use in severe psoriasis.
Med Lett Drugs Ther. 1997 Nov 7;39(1013):105-6 | Show Full IntroductionHide Full Introduction

Calcipotriene for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • August 5, 1994;  (Issue 928)
Calcipotriene ointment 0.005% (calcipotriol; Dovonex - Westwood Squibb), a synthetic vitamin D 3 analog previously available in Europe and Canada, has now been approved by the US Food and Drug Administration...
Calcipotriene ointment 0.005% (calcipotriol; Dovonex - Westwood Squibb), a synthetic vitamin D 3 analog previously available in Europe and Canada, has now been approved by the US Food and Drug Administration (FDA) for treatment of moderate plaque psoriasis, the most common form of the disease.
Med Lett Drugs Ther. 1994 Aug 5;36(928):70-1 | Show Full IntroductionHide Full Introduction